Sunday, 8 April 2001, evening - Registration

Reception and Buffet Dinner

Hosted by Anne Kristin Sydnes, Minister of International Development, Norway
Recital: Oystein Birkeland, cello and Vebjørn Anvik, piano

Monday, 9 April 2001

Morning - Opening Session

Welcome and keynote remarks

Sigrun Møgedal (State Secretary for International Development, Norway)

Gro Harlem Brundtland (Director General, WHO)

Adrian Otten (Director, Intellectual Property Division, WTO Secretariat)

Nils Daulaire (President and CEO, Global Health Council)

Peter Piot (Executive Director, UNAIDS)

Overview of agenda and methods of work

Morning - Session I - Access to Essential Drugs in Low-Income Countries: Key Issues

Role of government in health care
Patrick Kadama (Commissioner of Health, Uganda)

Healthcare and pharmaceutical systems in developing countries
Richard Laing (Boston University)

Tariffs and non-tariff trade harriers and access to essential drugs
Adrian Otten (WTO)

A research-based industry perspective
Harvey Bale (IFPMA)

Ensuring access to essential drugs - framework for action
Jonathan Quick (WHO)

Afternoon - Session II - The Role of Financing in Ensuring Access to Essential Drugs

Mobilization of domestic resources in developing countries

Suwit Wilbulproprasert (Ministry of Public Health, Thailand)
Paulo Teixeira (Ministry of Health, Brazil)

External assistance and pharmaceutical financing

Lieve Fransen (European Commission)
Françoise Varet (Government of France)

Health financing and access to health care

Jeffrey Sachs (Harvard University)

Afternoon - Session III - Differential Pricing: Concepts and Issues

Economic analysis

Patricia Danzon (University of Pennsylvania)
EM. Scherer (Harvard University)

Conceptual issues

Heinz Redwood (Industry Consultant)
Gunther Faber (GlaxoSmithKline)
Ellen ‘t Hoen (Médecins Sans Frontières)

Tuesday, 10 April 2001

Morning - Session IV - Current Experience with Differential Pricing

Experience with vaccines

Jacques-François Martin
(Global Fund for Children’s Vaccines)

Experience with contraceptives

Christian Saunders (UNFPA)

Experience with generic drugs

Cecile Miles (Ranbaxy)

Experience with HIV/AIDS-related drugs

Dorothy Ochola (Uganda Improved Access to HIV/AIDS Drugs)
John Wecker (Boehringer-Ingelheim)

Experience with access to essential medicines for tropical diseases

Maria Neira (WHO)

Experience with drug donations

Ivermectin: Jeffrey Sturchio (Merck & Co., Inc.)
Fluconazole: Chuck Hardwick (Pfizer, Inc.)

Morning - Session V - Market Segmentation: Techniques, Actors and Incentives

Marketing strategies by manufacturers and contractual approaches:

Market segmentation and price differentiation: a novel approach

Albert Itschner (Novartis)

Purchase undertakings (including security and prevention of diversion)

Keith McCullough (Vuna Healthcare Logistics)

Ex post reimbursement techniques

Clifford Wong (Kaiser Permanente, retired; MedImpact)

Governmental measures:

Role of regulatory authorities

Guy Woods (Lacuna Research, Ltd.)

Export controls

John Bisonga (Customs and Excise Department Kenya)

Afternoon - Session V (continued)

The use of intellectual property rights

Richard Wilder (Powell, Goldstein, Frazer & Murphy)
Carlos Correa (University of Buenos Aires)

Competition policy considerations

Harvey Applebaum (Covington & Burling)
Alberto Heimler (Autorita Garante della Concorrenza e del Mercato, Italy)

Afternoon - Session VI - Purchaser Perspectives and Incentives for Differential Pricing

ACAME bulk purchasing of essential drugs

Pascal Hessou (ACAME)

International procurement agency

Hanne Bak Pedersen (UNICEF)

Incentives for differential pricing (tax, legal, other measures)

Malaya Harper (Department for International Development, UK)

A consumer perspective

K. Balasubramaniam (Consumers International)

Market segmentation and international reference pricing

Ed Schoonveld (Cambridge Pharma Consultancy)

Wednesday, 11 April 2001

Morning - Session VII - Perspectives on Financing and Differential Pricing

A pharmacoeconomic perspective

David Henry (Newcastle University, Australia)

Public/private partnership

Seth Berkley (IAVI)

A developed country consumer perspective

Jamie Love (Consumer Project for Technology)

A pharmacy professional perspective

Mabel Torongo (International Pharmacy Federation)

A generic manufacturer’s perspective

Bill Haddad (Cipla)

A developed country government perspective

Paul Vandoren (European Commission, DG Trade)

A developing country government perspective

Desmond Johns (Government of South Africa)

A research-based industry perspective

Mark Speaker (Bristol-Myers Squibb, Co.)

Morning - Session VIII - Round-up Discussion

Synopses of main points

Designed & produced by the Difference Machine